Late relapses in acute myeloid leukemia: Analysis of characteristics and outcome

Dushyant Verma, Hagop Kantarjian, Stefan Faderl, Susan O'Brien, Sherry Pierce, Khanh Vu, Emil Freireich, Michael Keating, Jorge Cortes, Farhad Ravandi

Research output: Contribution to journalArticle

34 Scopus citations

Abstract

Relapse after 5 years of complete remission (CR) is uncommon in acute myeloid leukemia (AML). Among 2347 patients seen between 1980 and 2008, 1366 achieved CR; 942 relapsed. Eleven (1.16 of all relapses) relapsed after a CR of>5 years. The median age was 66 years (range, 3779). Initial therapy was cytarabine plus anthracycline in six, amsacrine-based in three, and other in two. The median CR1 duration was 81 months (range, 60137). At relapse, the karyotype was different from the initial finding in five of eight (63) patients with available data. Treatment for relapse included cytarabine with anthracycline in eight, and other in three patients, with a second CR (CR2) achieved in four (36). The median CR2 duration was 1 month (range, 037), and median survival after relapse was 6.4 months (range, 139). Late relapses in AML are infrequent, with poor response to therapy. Karyotype at relapse is frequently different, raising the question of second AML versus relapse with the original clone.

Original languageEnglish (US)
Pages (from-to)778-782
Number of pages5
JournalLeukemia and Lymphoma
Volume51
Issue number5
DOIs
StatePublished - May 1 2010
Externally publishedYes

Keywords

  • Acute myeloid leukemia
  • AML
  • Late relapse

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Late relapses in acute myeloid leukemia: Analysis of characteristics and outcome'. Together they form a unique fingerprint.

  • Cite this

    Verma, D., Kantarjian, H., Faderl, S., O'Brien, S., Pierce, S., Vu, K., Freireich, E., Keating, M., Cortes, J., & Ravandi, F. (2010). Late relapses in acute myeloid leukemia: Analysis of characteristics and outcome. Leukemia and Lymphoma, 51(5), 778-782. https://doi.org/10.3109/10428191003661852